Episode Details
Back to Episodes
Marvel Biosciences Nears Human Trials as MB-204 De-Risks Autism & Alzheimer’s | TSX-V: MRVL | The Capital Compass
Description
In this episode of The Capital Compass, listeners hear directly from Marvel Biosciences as the company advances its lead neuroscience asset, MB-204, toward first-in-human trials. With granted composition-of-matter IP, completed toxicology, and compelling pre-clinical data across autism, Rett syndrome, Fragile X, and Alzheimer’s disease, Marvel is approaching a key inflection point.
This episode covers:
How MB-204 targets the adenosine A2A receptor across multiple CNS indications
Autism and Rett syndrome data outperforming approved therapies
Alzheimer’s tau findings presented at AAIC
Investor confidence, capital structure, and global IP strategy
Near-term catalysts as Marvel prepares for clinical entry
This podcast is made in partnership with Marvel Biosciences Corp. This podcast is for informational purposes only. Please do your own due diligence. For our full disclaimer, visit: https://themarketonline.ca/disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.